Table 3.

Characteristics of treatments. UI/mL: International units per millilitre; subconj. inj.: subconjunctival injection; M: million; mL: millilitre.

Publication data	Intervention
First author	Group 1				–
	Intervention	No. of patients	Dose	Administration	Intervention	No. of patients	Dose	Administration
Sturges et al.34	Excision	14		Excision with 4 mm surgical margins and removal a thin scleral flap beneath the tumor	IFN	15	Solution 1 M IU/mL	4 × 1 drop/day
Tanabe et al.35	Excision	5		Excision with 3 mm surgical margins	MMC	5	0.04%	4 × 1 drop/day; 1 week on–1–2 weeks off
Nanji et al.17	Excision	49		Excision (4 mm margins) + freeze thaw cryotherapy (41 case), + intraoperative mitomycin C was (1 case), + sclerectomy (6 cases) Amniotic membrane (14 cases), conjunctival autograft in 1 case	IFN	49	drop: 3 M IU (in 0.5 mL); inj.:1 M IU/mL; drop + inj: 3 M IU/mL	4 × 1 drop/day
Chaugule et al.36	IFN	5	Intron A powder reconstituted to topical 1 M IU/mL	4 × 1 drop/day for 3 months	5-FU	1	Concentration of 1%	4 × 1 drop/day for 2 weeks
Kusumesh et al.37	IFN	26	1 mL of recombinant IFNa2b injection + 2 mL of 0.9% NaCl	4 × 1 drop/day	MMC	25	2 mg powder with 5 mL of 0.9% NaCl	4 × 1 drop/day, (0.4 mg/mL or 0.04%) week-on–week-off regimen
Venkateswaran et al.38	IFN	48	Concentration of 1 M IU/mL	4 × 1 drop/day, no pause	5-FU	54	Concentration of 1%	4 × 1 drop for 1 week on–3 weeks off
Polski et al.13	Excision	12		Excisional biopsy with no-touch technique + double freeze–thaw cryotherapy along conjunctival margins	IFN, MMC, 5-FU	10	5-FU—1%; MMC (0.02%); IFN drop (1 million IU/mL); IFN inj (3 million IU in 0.5 mL	5-FU 4 × 1 drop/day—(2 weeks on–2 weeks off × 2 courses), MMC 4 × 1 drop/day—(2 weeks on–2 weeks off × 2 courses), IFN 4 × 1 drop/day—(4–6 months continuously), and/or IFN-a2b subconj inj. 3–6 injections—weekly)